Special Issue "Pancreatic Cancer"

Guest Editor
Dr. Christian Pilarsky
Klinik und Poliklinik für Viszeral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany
Website: http://vtg.uniklinikum-dresden.de/Pankreaslabor/
E-Mail:
Phone: +49 351 458 166 07
Fax: +49 351 449 210 303
Interests: pancreas cancer; apoptosis; microarrays; signal transduction networks; tumor stroma interaction; prostate cancer; biomarker

Dear Colleagues,

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies in industrialized countries. It is characterized by early metastasis and aggressive, infiltrative growth along the endothelium basement membrane and neurons. However, in recent years the crucial genetic changes leading to pancreatic cancer have been indentified. Genetic analyses of patient samples have shown that the vast majority of those cancers display mutations in KRAS and the p16 locus. Despite these advancements PDAC shows an overall five-year survival rate of only 5%. Therefore new efforts have to be made in the field of translational oncology to improve the understanding, the diagnosis and the therapy of this disease.Apart from PDAC there are other pancreatic cancer types, which differ highly in patient outcome due to their tissue origin and genetic make up. Cancers like intraductal papillary mucinous neoplasia are of growing concern to the physicians and researchers in the field. This issue will focus on the recent key findings in the field of pancreatic cancer research and therapy. It will contain different articles regarding the different types of pancreatic cancer, the latest research and new strategies to improve the therapy of this disease.

Dr. Christian Pilarsky
Guest Editor

Submission

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed Open Access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 500 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.

• pancreas
• cancer
• tumor suppressor gene
• oncogene
• KRAs
• p53
• SMAD
• gene function
• ultrasound
• adjuvant
• neoadjuvant therapy
• epithelial mesenchymal transition
• stem cells
• apoptosis
• zeb1
• chemoresistance
• survival prediction